How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study

@article{Mamtani2016HowOD,
  title={How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study},
  author={Anita Mamtani and Andrea V. Barrio and Tari A King and Kimberly J Van Zee and George Plitas and Melissa L Pilewskie and Mahmoud B. El-Tamer and Mary L Gemignani and Alexandra Simkovich Heerdt and Lisa M. Sclafani and V S Sacchini and Hiram S. Iii Cody and Sujata Babaso Patil and Monica Morrow},
  journal={Annals of Surgical Oncology},
  year={2016},
  volume={23},
  pages={3467-3474}
}
BackgroundIn breast cancer patients with nodal metastases at presentation, false-negative rates lower than 10 % have been demonstrated for sentinel node biopsy (SLNB) after neoadjuvant chemotherapy (NAC) when three or more negative sentinel nodes (SLNs) are retrieved. However, the frequency with which axillary dissection (ALND) can be avoided is uncertain.MethodsAmong 534 prospectively identified consecutive patients with clinical stages 2 and 3 cancer receiving NAC from November 2013 to… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 28 CITATIONS

Is it always necessary to perform an axillary lymph node dissection after neoadjuvant chemotherapy for breast cancer?

  • Annals of the Royal College of Surgeons of England
  • 2019
VIEW 3 EXCERPTS
CITES RESULTS, METHODS & BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 30 REFERENCES

Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2015
VIEW 1 EXCERPT